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Abstract
Mild traumatic brain injury (mTBI) results in variable clinical trajectories and outcomes. The 
source of variability remains unclear, but may involve genetic variations, such as single nucleotide 
polymorphisms (SNPs). A SNP in catechol-o-methyltransferase (COMT) is suggested to influence 
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development of post-traumatic stress disorder (PTSD), but its role in TBI remains unclear. Here, 
we utilize the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot 
(TRACK-TBI Pilot) study to investigate whether the COMT Val158Met polymorphism is 
associated with PTSD and global functional outcome as measured by the PTSD Checklist – 
Civilian Version and Glasgow Outcome Scale Extended (GOSE), respectively. Results in 93 
predominately Caucasian subjects with mTBI show that the COMT Met158 allele is associated 
with lower incidence of PTSD (univariate odds ratio (OR) of 0.25, 95% CI [0.09–0.69]) and 
higher GOSE scores (univariate OR 2.87, 95% CI [1.20–6.86]) 6-months following injury. The 
COMT Val158Met genotype and PTSD association persists after controlling for race (multivariable 
OR of 0.29, 95% CI [0.10–0.83]) and pre-existing psychiatric disorders/substance abuse 
(multivariable OR of 0.32, 95% CI [0.11–0.97]). PTSD emerged as a strong predictor of poorer 
outcome on GOSE (multivariable OR 0.09, 95% CI [0.03–0.26]), which persists after controlling 
for age, GCS, and race. When accounting for PTSD in multivariable analysis, the association of 
COMT genotype and GOSE did not remain significant (multivariable OR 1.73, 95% CI [0.69–
4.35]). Whether COMT genotype indirectly influences global functional outcome through PTSD 
remains to be determined and larger studies in more diverse populations are needed to confirm 
these findings.
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1. Introduction
Traumatic brain injury (TBI) is a common and often debilitating injury in modern societies. 
In the United States alone, at least 2.5 million people suffer TBIs annually which accounts 
for 52,000 deaths, 275,000 inpatient hospitalizations, and 1,365,000 Emergency Room visits 
[1]. Approximately 70–90% of all TBI is characterized as ‘mild TBI’ (mTBI) defined by a 
Glasgow Coma Scale score of 13–15. The vast majority of patients make a complete 
recovery following mTBI in the ensuing weeks to months [2,3]. However, a small but 
significant number of patients suffer from persistent neurologic, cognitive and/or 
neuropsychiatric sequelae – including headache, dizziness, fatigue, memory impairment, 
slowed processing speed, depression and post-traumatic stress disorder (PTSD), among 
others [4]. In many instances, individuals enduring similar mechanisms and magnitude of 
brain injury follow different clinical trajectories, and there are limited metrics to identify 
and/or sub-stratify those at greatest risk for persistent post-traumatic impairment [5].
The Human Genome Project has allowed the identification of single nucleotide 
polymorphisms (SNPs) – single nucleotide substitutions which alter amino acid sequence 
and protein function and/or levels of protein expression. Several SNPs are good candidates 
for allelic association studies aimed at explaining the divergence in outcome or in the 
prevalence of cognitive, behavioral and neuropsychiatric symptoms following TBI [6–8]. 
Catechol-O-methyltransferase (COMT; encoded by the gene COMT on chromosome 
22q11.2) represents one such candidate gene. COMT enzymatically inactivates the 
catecholamine neurotransmitters, i.e., norepinephrine and dopamine, through 3-O-
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methylation of the benzene ring [9]. A common coding SNP, Val158Met (rs4680), results in a 
substitution of valine (G; Val158) for methionine (A; Met158) at codon 158. The Met158 
substitution reduces COMT enzymatic activity [10,11]. In areas with limited reuptake 
transporters, i.e., the prefrontal cortex, COMT-mediated inactivation is the principal 
mechanism of inactivation of dopaminergic signal transmission, and the Met158 variant is 
associated with higher catecholamine bioavailability [12–14].
Numerous studies have investigated the effects of the COMT Val158Met polymorphism on 
human behavior and/or brain function [9,15,16]. In general, the Met158 allele confers a 
performance advantage in cognitive tasks – including measures of memory and attention – 
attributed to the higher catecholamine bioavailability in the prefrontal cortex [9,15–17]. The 
Val158 allele, on the other hand, may confer advantage in aversive stimulus processing [18]. 
Consistent with this principle, the Met158 allele has been associated with a number of 
anxiety disorders – including generalized anxiety disorder, panic disorder, obsessive 
compulsive disorder, and PTSD in some, but not all study populations [19–23]. In TBI, prior 
studies have shown that Val158/Val158 homozygosity may be associated with greater 
impairment in certain cognitive domains, e.g., perseveration, but not others [24–27]. 
However, whether the COMT Val158Met polymorphism influences psychiatric health 
following brain injury – such as TBI – has yet to be studied.
PTSD is a relatively common and often debilitating neuropsychiatric sequela of TBI with 
published rates ranging from of 17% to 33% of patients [28–32]. The Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) classifies PTSD as an anxiety 
disorder presenting with three concurrent symptom clusters after exposure to a traumatic 
event: persistent re-experiencing of the traumatic event, persistent avoidance of stimuli 
associated with the traumatic event, and persistent symptoms of increased arousal. The event 
can involve actual or perceived serious injury, a threat to one’s physical integrity or the 
integrity of another individual, or an unexpected death or serious harm to a close family 
member or friend. The symptoms must be present for more than one month and cause 
clinically significant distress or impairment in social, occupational, or other important areas 
of functioning [33]. Although PTSD may occur with any severity of TBI, the highest 
incidence occurs in individuals with mTBI [31,34–36]. Furthermore, symptoms of PTSD in 
the context of a history of mTBI is often associated with poorer outcome [37].
In this study we utilize the Transforming Research and Clinical Knowledge in Traumatic 
Brain Injury Pilot (TRACK-TBI Pilot) dataset, a comprehensive database of demographic 
history, biomarkers, neuroimaging, and neuropsychiatric and neurocognitive outcomes [38], 
to investigate whether the COMT Val158Met polymorphism is associated with the 
development of symptoms meeting DSM-IV criteria of PTSD and global functional outcome 
following isolated and uncomplicated mild closed head injury. On the basis of the literature 
of anxiety disorders, we hypothesize that subjects with the Met158 allele will more 
frequently develop symptoms associated with PTSD and have poorer 6-month global 
functional outcome following mTBI.
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2. Materials and methods
2.1. Study design
The TRACK-TBI Pilot Study is a multicenter prospective observational study conducted at 
three Level 1 Trauma Centers in the United States – San Francisco General Hospital, 
University of Pittsburgh Medical Center and University Medical Center Brackenridge 
(UMCB) in Austin, Texas [38]. Institutional review board approval was obtained at all 
participating sites. Informed consent was obtained for all subjects prior to enrollment in the 
study. For patients unable to provide consent due to their injury, consent was obtained from 
their legally authorized representative (LAR). Patients were then re-consented, if cognitively 
able at later inpatient and/or outpatient follow-up assessments for continued participation in 
the study.
2.2. Patient selection
Inclusion criteria for the pilot study were patients presenting to a Level I trauma center with 
external force trauma to the head and clinically indicated head computed tomography (CT) 
scan within 24 h of injury. TRACK-TBI Pilot patients age ⩾16 completed outcome 
measures. Exclusion criteria were pregnancy, comorbid life-threatening disease, 
incarceration, serious psychiatric and neurologic disorders that would interfere with outcome 
assessment, and non-English speakers due to limitations in participation with outcome 
assessment. For the present study, our goal was to study the effects of COMT Val158Met in 
isolated and uncomplicated mTBI. Therefore, our analysis was restricted to a subset of 
patients with a GCS ⩾13, loss of consciousness (LOC) <30 min, post-traumatic amnesia 
<24 h, no skull fracture or acute intracranial pathology – defined as the absence of 
intraparenchymal contusions or hemorrhage, axonal injury, ventricular hemorrhage, epidural 
hematoma, acute subdural hematoma or traumatic subarachnoid hemorrhage – on non-
contrasted head CT, and no polytrauma as defined by an Abbreviated Injury Scale (AIS) 
score >1 in any extracranial body region. To avoid potential confounding with measures of 
PTSD, patients who reported pre-injury PTSD or schizophrenia – variables known to 
associate with COMT – were excluded from the present study [39,40]. Patients with 
previous cerebrovascular accidents, brain tumor, and baseline developmental delay were also 
excluded.
2.3. Biospecimen collection and genotyping
Specimen acquisition was performed as previously described [38]. In brief, blood samples 
for DNA genotyping analysis were collected via peripheral venipuncture or existing 
peripheral venous indwelling catheters within 24 h of injury. Samples were collected in BD 
Vacutainer K2-EDTA vacutainer tubes, and subsequently aliquoted and frozen in cryotubes 
at −80 °C within 1 h of collection in accordance with recommendations from the NIH-CDE 
Biomarkers Working Group [41]. DNA was extracted from isolated leukocytes using the 
Wizard® Genomic DNA Purification Kit as described by the manufacturer (Promega, 
Madison, WI). COMT Val158Met polymorphism (rs4680) was genotyped utilizing 
TaqMan®SNP Genotyping Assay as described by the manufacturer (Applied Biosystems, 
Carlsbad, CA). For the purposes of evaluating a potential protective benefit of the Met158 
allele, Met158/Met158 and Met158/Val158 were combined as a single group as previously 
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described for COMT [42–45], and other genetic polymorphisms in TBI [46–48]. Therefore, 
for data recording and all figures this group is referred to as Met158.
2.4. Neuropsychiatric assessment and outcome parameters
All participants underwent a neuropsychiatric and outcome assessment at 6 months 
following TBI, including the PTSD Checklist – Civilian Version (PCL-C) and the Glasgow 
Outcome Scale Extended (GOSE). To evaluate for the presence of PTSD, the PCL-C was 
utilized as previously described [49–51]. The PCL-C is a standardized self-report rating 
scale of 17 PTSD symptoms that can be mapped to the three required criteria for PTSD, as 
outlined in the DSM-IV. Respondents are asked to rate on a 5-point scale (1- “not at all” to 
5-“extremely”) how much they have been bothered by each symptom in the past month. 
Subjects endorsing a score of ⩾3 in one or more symptoms in “Re-experiencing”, three or 
more symptoms in “Avoidance”, and two or more symptoms in the “Hypervigilance” 
categories on the PCL-C were coded as “Yes PTSD” during analysis in accordance to the 
DSM-IV clinical screening criteria for PTSD.
The GOSE was utilized to assess global functional outcome following TBI as previously 
described [52]. The GOSE provides an overall measure of disability based on information 
obtained through a structured interview focused on cognition, independence, employability, 
and social/community participation. Individuals are described by one of the eight ordinal 
outcome categories: 1-Dead, 2-Vegetative State, 3-Lower Severe Disability, 4-Upper Severe 
Disability, 5-Lower Moderate Disability, 6-Upper Moderate Disability, 7-Lower Good 
Recovery, and 8-Upper Good Recovery.
2.5. Statistical analysis
Group differences in baseline descriptors across COMT Met158 carriers versus Val158/Val158 
homozygotes were assessed by Pearson’s chi-squared test (χ2) for categorical variables, and 
analysis of variance (ANOVA) for continuous variables. Fisher’s Exact Test was used to 
assess differences in categorical variables with cell counts ≤5. Predictors examined in 
addition to COMT genotype were selected on the basis of prior published reports, and 
limited to variables that were previously associated with the response variable and relevant 
within our study population of isolated, uncomplicated mTBI to help control for potential 
confounding in multivariable analyses. Given the constraints of our exclusion criteria, 
remaining variables known to associate with PTSD include the presence of a self-reported 
pre-existing psychiatric disorder (defined by the major categories of diagnosed depression, 
anxiety, sleep disorder, and bipolar disorder) and history of substance abuse [2,53–55]. For 
GOSE, age (per-year increase) and GCS (15 vs. 13–14) were selected as consistent 
predictors cited in literature [56]. Binary logistic regression was performed with PTSD as 
the response, and COMT genotype, presence of pre-existing psychiatric disorder, and illicit 
drug use history as predictors. Ordinal logistic regression was performed with GOSE as the 
response, and COMT genotype, age, and GCS as predictors. All multivariable regression 
models conformed to tests for goodness-of-fit. The Nagelkerke pseudo-R-square (NR2) used 
to estimate the variance explained by the model. Race effects were independently assessed 
in the presence of COMT genotype for each response. Significance was assessed at α = 
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0.05. All analyses were performed using Statistical Package for the Social Sciences (SPSS) 
v.21 (IBM Corporation, Chicago, IL).
3. Results
3.1. Demographic and clinical descriptors
In total, the present study included 93 subjects (Table 1). Overall, the mean age of included 
subjects was 40 years old, and the majority of subjects were male (60%). Subjects were 
predominately Caucasian (70%). Subjects also self-identified as African American (14%), 
Asian (7%), mixed race (7%), American Indian/Native Alaskan (2%) or Hawaiian/Pacific 
Islander (2%). With respect to psychiatric health, 39% of subjects had self-reported presence 
of one or more psychiatric conditions – including depression, anxiety, sleep disorder, or 
bipolar disorder – and 24% percent of subjects reported a history of substance abuse. 
Subjects had a multitude of different mechanisms of injury including motor vehicle or 
motorcycle collision, bicycle accident, pedestrian versus automobile, assault and struck by 
or against an object. COMT genotype distribution was 29% Met158/Met158 (n = 27), 46% 
Met158/Val158 (n = 43) and 25% Val158/Val158 (n = 23). COMT allelic frequencies (A = 
0.53, G = 0.47) were not found to deviate significantly from Hardy–Weinberg equilibrium 
(X2 = 0.5, p = 0.778). A higher prevalence of African-Americans (p = 0.032) and preexisting 
psychiatric disorder (p = 0.043) were noted in the Val158/Val158 homozygotes. No other 
significant differences were observed in the distribution of each demographic and clinical 
descriptor across COMT Met158 and Val158/Val158 genotypes (Table 1).
3.2. COMT is associated with PTSD independent of pre-existing psychiatric disease, 
substance abuse and race
We first tested our hypothesis that COMT Met158 is associated with higher incidence of 
PTSD following mTBI. In total, 28 of 96 subjects (29%) qualified for PTSD on screening 
criteria. Sixteen of 73 (22%) of Met158 carriers and 12 of 23 (52%) of Val158/Val158 
homozygotes met qualifying screening criteria for PTSD, respectively (X2 = 7.75, p = 0.005) 
(Fig. 1). COMT Met158 had a univariate odds ratio (OR) of 0.25 (95% CI [0.09–0.69], NR2 
11.0%) for the presence of PTSD (Table 2). Therefore, contrary to our initial hypothesis, 
COMT Met158 was associated with lower incidence of PTSD.
Given that COMT genotype unevenly distributed across racial subgroups, we next utilized 
multivariable regression for PTSD to control for the potential confounding influence of race. 
In the studied population, univariate analysis failed to show a statistically significant 
relationship between race and PTSD following mTBI (p = 0.092). When only the two largest 
racial groups were compared populations were compared (Caucasian and African 
American), African American race emerged as a predictor for PTSD with a univariable OR 
of 3.89 (95% CI [1.13–13.35]). However, only COMT genotype, but not African American 
racial background, remained a statistically significant predictor of PTSD when included in a 
multivariable model as evidenced by a multivariable OR of 0.29 (95% CI [0.10–0.83]) and 
2.76 (95% CI [0.75–10.22]) for the COMT Met158 allele and African American race, 
respectively. Collectively, these data preliminarily suggest that the association of COMT and 
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PTSD is not influenced by race, but larger future studies in more diverse populations are 
needed to confirm and/or refute these findings.
We next sought to determine whether controlling for established risk factors for PTSD, e.g., 
pre-existing psychiatric disease and substance abuse [2,53–55], would influence the 
observed association between COMT genotype and PTSD. Univariate analysis confirmed 
that pre-existing psychiatric disorder (OR 6.85, 95% CI [2.54–18.49], NR2 22.6%) and 
substance abuse (OR 3.44, 95% CI [1.26–9.38], NR2 8.6%) was associated with greater 
univariate odds of PTSD (Table 2). We also confirmed that there was no effect of interaction 
between COMT and preexisting psychiatric disorder on PTSD (p = 0.195). We then 
performed multivariable regression with PTSD as the response and COMT, preexisting 
psychiatric disorder, and substance abuse as predictors. In the multivariable model COMT 
Met158 remained a significant predictor of decreased odds of PTSD (OR 0.32, 95% CI 
[0.11–0.97]) after adjusting for pre-existing psychiatric disorder and illicit drug use. In the 
model, pre-existing psychiatric disorder associated with greater odds of PTSD (OR 5.17, 
95% CI [1.80–14.89]) while drug use did not significantly associate with PTSD (Table 2). 
This model was statistically significant (p = 8.1 × 10−5) and explained 29.5% of the 
variability in PTSD – values higher than COMT Met158 or any pre-existing risk factor alone.
3.3. Functional outcome is associated with COMT and inversely related to PTSD
We next investigated whether an association exists between COMT Met158 carriers or 
Val158/Val158 homozygotes and functional outcome following mTBI. For the 70 COMT 
Met158 carriers, 6%, 17%, 37%, and 40% were found to have GOSE scores of 5, 6, 7, 8, 
respectively. In comparison, 35%, 9%, 30% and 26% of the 23 COMT Val158/Val158 
homozygotes were found to have GOSE scores of 5, 6, 7, 8, respectively, which differed 
from Met158 carriers (p = 0.008) (Fig. 2). Univariate ordinal logistic regression showed that 
the presence of COMT Met158 allele was associated with an OR of 2.87 for higher GOSE 
scores (95% CI [1.20–6.86]) and explained 5.9% of the variance. Race was not a significant 
univariate predictor of GOSE (p = 0.158). After correcting for age (per-year increase: 
univariate OR 0.99, 95% CI [0.97–1.02]; multivariable OR 0.99, 95% CI [0.97–1.02]), and 
no GCS deficit (GCS 15: univariate OR 2.55 95% CI [1.00–6.57]; multivariable OR 2.68, 
95% CI [1.03–6.94]), COMT Met158 remained a significant predictor of higher functional 
outcome on GOSE (OR 2.96, 95% CI [1.23–7.13], NR2 6.2%).
Given the lower incidence of PTSD with COMT Met158, we sought to determine whether 
the observed association between GOSE and COMT may in part be explained by the 
differences in the incidence of post-TBI PTSD between COMT Met158 carriers or Val158/
Val158 homozygotes. Overall, low GOSE scores were associated with a higher incidence of 
PTSD (Fig. 3A–C) Among all subjects and Met158 carriers a statistically significant increase 
in PTSD was observed with decreasing GOSE groups as reflected by p-values of 5.32 × 10−7 
and 2.27 × 10−5, respectively (Fig. 3A and B). Overall a similar trend was observed in 
Val158/Val158 homozygotes (Fig. 3C), but this failed to reach statistical significance (p = 
0.087). Collectively, this suggests that PTSD may influence functional outcome as 
previously described for other outcome metrics [57].
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To offer further support to this hypothesized relationship, we verified that PTSD is a 
univariate predictor of lower GOSE by ordinal logistic regression (OR 0.08, 95% CI [0.03–
0.21]), and explains 30.6% of the variance in GOSE. We next performed a multivariable 
ordinal logistic regression with COMT Met158 and PTSD as predictors, and GOSE as the 
dependent variable, adjusting for age. The model was statistically significant (p = 9.06 × 
10−7) and explained 32.8% of the variability in GOSE. Analysis confirmed that PTSD was 
associated with greater odds of lower GOSE score as evidenced by multivariable OR of 0.09 
(95% CI [0.03–0.26]), but the association of COMT with global functional outcome was no 
longer statistically significant (multivariable OR 1.73, 95% CI [0.69–4.35]) (Table 3). These 
analyses suggest that PTSD is inversely associated with GOSE and may indirectly contribute 
to the association of COMT and GOSE following mTBI. However, the directionality of this 
relationship could not be conferred by the present analysis and future studies are needed to 
more clearly delineate the influences of PTSD on functional outcome.
4. Discussion
In the present study, we sought to investigate whether the COMT Val158Met polymorphism 
is associated with PTSD and functional outcome following mild closed head injury in a 
predominately Caucasian population. We found that subjects with the COMT Met158 allele 
have lower rates of PTSD and better functional outcomes when compared to Val158/Val158 
homozygotes at 6-months following injury. Much of the effect on functional outcome may 
be related to differences in PTSD between COMT genotypes. How PTSD relates to outcome 
measures, such as GOSE, remains unclear and future studies addressing this issue are 
needed.
Prior reports examining the potential influence of the COMT Val158Met polymorphism on 
long-term outcomes following TBI have been predominately restricted to measures of 
cognition in patients with predominantly moderate and severe TBI, with varying results [24–
27]. Consistent with a potential deleterious role of COMT Val158/Val158 in TBI, 
homozygotes have been shown to have a greater number of perseverative errors following 
TBI [24,25]. More recently, no relationship between the COMT Met158-Val genotype and 
cognitive performance was found; however, this study did not include measures of 
perseveration. The authors also failed to find an association between COMT Val158Met 
polymorphism and functional outcome as measured by the GOSE at 12 and 24 months post-
injury [27]. The source of this discrepancy with the present report is unclear. The incidence 
of PTSD is greatest following mTBI [31,34–36], and greater impairment of cognition or 
prolonged amnesia with more severe TBI may protect against development of subsequent 
PTSD [58]. Therefore, subjects with more severe injury as studied by Willmott et al., 2014, 
may not show similar outcome associations in the absence of PTSD. Whether this reflects 
differences in severity of injury in its entirety and/or trial design – namely interval of follow-
up (6-months vs. 12- and 24-months) – or a combination thereof remains to be determined.
To the best of our knowledge, no prior reports have been published investigating the 
relationship between the COMT Val158Met polymorphism and development of PTSD 
following head trauma. The rate of PTSD of 26.5% in this study is within the published 
range for mTBI [28–32]. The role of COMT in the development of PTSD following other 
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forms of emotional and/or physical trauma remains unclear [21–23,59]. For example, in 
survivors of the Rwandan genocide, COMT Met158/Met158 homozygotes demonstrated 
higher risk for PTSD independent of their traumatic load [21]. The COMT Met158 allele has 
also been associated with PTSD following urban violence [22]. However, these studies were 
conducted in an African and Brazilian population, respectively. It has recently been 
demonstrated that COMT Val158Met polymorphism exerts differential effects on risk of 
PTSD in children or different ethnic groups [20]; this suggests that different ethnic 
backgrounds and presumably heterogeneity of genetic modifiers therein modulates the 
effects of the COMT Val158Met polymorphism on genetic propensity for PTSD. Consistent 
with this principle, a study of predominately Caucasian veterans following deployment to 
Iraq failed to find an association between Met158/Met158 and more prevalent PTSD, but did 
demonstrate that Met158/Val158 heterozygotes developed fewer PTSD symptoms than either 
homozygous group [59]. Gene functions and associated phenotypic manifestations are 
modified through a complex interplay with environmental stimuli [6]. Therefore, whether 
the predominately Caucasian population, the nature and severity of traumatic event and/or 
combination thereof contribute to the potentially protective effect of the COMT Met158 
allele following mTBI remains to be seen. We show that the association between COMT and 
PTSD following mTBI persists despite controlling for race. However, stratification of our 
population into racial groups showed a trend towards lower PTSD with the presence of the 
COMT Met158 allele in all racial groups, but failed to reach statistical significance which 
was in part likely the result of the small sample size of each racial group. Larger studies are 
therefore needed to fully delineate the potential modifying influence of ethnicity on 
behavioral and psychiatric associations with COMT Val158Met in the setting of head trauma.
The mechanism(s) through which COMT influences propensity to develop PTSD also 
remain unclear. In support of a potentially protective role of the COMT Met158 allele, a 
recent study has shown that COMT Val158/Val158 homozygotes are associated with 
heightened reacquisition of fear from presumed alterations in reconsolidation of fearful 
memories [42]. Conversely, the COMT Met158 allele has been also been associated with 
impaired fear extinction in some, but not all studies [60,61], and may therefore increase 
propensity for PTSD development in other contexts. However, a detailed review of the 
hypothesized mechanisms is beyond the scope of the present study.
Although we designed our study with restrictive inclusion criteria, it is not without 
limitations. Our data was obtained for a relatively small sample size (n = 93) in a 
predominately Caucasian male population and did not conform to known HapMap Phase III 
subpopulations; therefore, the need for studies in larger and more diverse study populations 
cannot be overstated. We also included patients only with isolated mTBI in the absence of 
intracranial findings on CT and a limited period of diminished consciousness and/or post-
traumatic amnesia; thus, the generalizability of our results is limited. We pursued analyses 
designed to investigate a hypothesized relationship between the COMT Val158Met 
polymorphism and PTSD and did not explore the structure–function implications of COMT 
with specific brain pathology or variables important to the trajectory of recovery such as 
treatment and support. There is also a need to examine gene-gene interaction with other 
susceptibility loci in the context of mTBI to better elucidate complex interactions and 
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mechanisms through which the COMT molecular pathway may influence response and 
recovery to TBI.
4.1. Conclusions
The COMT Val158Met polymorphism (rs4680) is associated with incidence of PTSD and 
functional outcome following isolated, uncomplicated mTBI. The COMT Met158 allele is 
associated with lower incidence of PTSD and improved functional outcome, and may exert a 
protective effect. However, larger studies in more diverse populations are needed to confirm 
the role of COMT Met158Val in psychological health following mTBI. Whether COMT 
Val158/Val158 homozygotes would benefit from heightened clinical surveillance and/or 
pharmacologic and behavior therapy targeted towards symptomatic manifestations of PTSD 
remain to be determined and should be the subject of future studies.
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Fig. 1. 
The COMT Val158Met polymorphism is associated with lower prevalence of qualifying for 
screening criteria for post-traumatic stress disorder (PTSD) at 6-months following mild 
traumatic brain injury. White, did not meet PTSD qualification on screening criteria; red, 
met PTSD qualification on screening criteria. COMT = Catechol-O-Methyltransferase. red, 
met PTSD qualification on screening criteria.
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Fig. 2. 
The COMT Val158Met polymorphism is associated with greater global functional outcome 
as measured by the Glasgow Outcome Scale Extended (GOSE) at 6-months following mild 
traumatic brain injury. White, GOSE score of 8; light gray, GOSE score of 7; dark gray, 
GOSE score of 5; red, GOSE score of 5. COMT = Catechol-O-Methyltransferase.
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Fig. 3. 
Global functional outcome is negatively associated with the presence of concomitant post-
traumatic stress disorder at 6-months post-injury. (A–C) Graphs depicting proportion of 
individuals not meeting (white) or meeting (red) post-traumatic stress disorder (PTSD) 
screening criteria in all subjects (A), subjects with the COMT Met158 allele (B), and subjects 
with COMT Val158/Val158 homozygosity (C). COMT = Catechol-O-Methyltransferase.
Winkler et al. Page 17
J Clin Neurosci. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Winkler et al. Page 18
Table 1
Demographic and clinical information of included subjects with mild traumatic brain injury.
Variable Met158
(N = 70)
Val158/Val158
(N = 23)
Significance
(p)
Age (y)
 Mean ± SD 40 ± 17 42 ± 14 0.682
Gender
 Male 42 (60%) 14 (61%) 0.941
 Female 28 (40%) 9 (39%)
Race
 Caucasian 52 (80%) 13 (20%) 0.032
 African-American/African 6 (46%) 7 (54%)
 Other races 12 (80%) 3 (20%)
Pre-existing psychiatric disorder
 No 47 (67%) 10 (44%) 0.043
 Yes 23 (33%) 13 (56%)
Substance abuse
 No 56 (80%) 15 (65%) 0.148
 Yes 14 (20%) 8 (35%)
Mechanism of injury
 Motor vehicle crash 22 (31%) 2 (9%) 0.140
 Cyclist/pedestrian hit 15 (21%) 6 (26%)
 Fall 21 (30%) 8 (35%)
 Assault 8 (11%) 6 (26%)
 Struck by/against object 4 (6%) 1 (4%)
ED arrival GCS
 13 1 (1%) 0 (0%) 0.817
 14 12 (17%) 5 (22%)
 15 57 (81%) 18 (78%)
Race distributions are reported as row percentages. All other distributions reported as column percentages. The race subgroup “Other races” was 
combined due to individual small sample sizes of Asian (N = 6; Met158 = 5, Val158/Val158 = 1), American Indian/Alaskan Native (N = 1; 
Met158 = 1), Hawaiian/Pacific Islander (N = 2; Met158 = 1, Val158/Val158 = 1), and more than one race (N = 6; Met158 = 5, Val158/Val158 = 
1).
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Table 2
Univariate and multivariable statistical analysis of the association between the COMT Val158Met 
polymorphism and a history of preexisting psychiatric disease or substance abuse with post-traumatic stress 
disorder (PTSD) at 6-months post-injury.
Predictor Odds ratio (OR) [95% CI] Predictor sig. (p) Nagelkerke pseudo-R2 Model sig. (p)
Univariate analysis
 COMT Met158 0.25 [0.09–0.69] 0.006 11.0% –
 Preexisting psychiatric disorder 6.85 [2.54–18.49] 6.3 × 10−5 22.6% –
 Substance abuse 3.44 [1.26–9.38] 0.016 8.6% –
Multivariable analysis
 COMT Met158 0.32 [0.11–0.97] 0.044 29.5% 8.1 × 10−5
 Preexisting psychiatric disorder 5.17 [1.80–14.89] 0.002 – –
 Substance abuse 1.88 [0.60–5.88] 0.281
OR >1 represents greater odds of having six-month PTSD. CI = Confidence Interval; COMT = Catechol-O-Methyltransferase; OR = Odds Ratio; 
PTSD = post-traumatic stress disorder.
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Table 3
Univariate and multivariable statistical analysis of the association between the COMT Val158Met 
polymorphism and post-traumatic stress disorder (PTSD) with global functional outcome (GOSE) at six 
months post-injury.
Predictor Odds ratio (OR) [95% CI] Predictor sig.(p) Nagelkerke pseudo-R2 Model sig. (p)
Univariate analysis
 COMT Met158 2.87 (1.20–6.86) 0.018 5.9% –
 PTSD 0.08 [0.03–0.21] 3.62 × 10−7 30.6% –
 Age (y) 0.99 [0.97–1.02] 0.499 0.5% –
 No GCS deficit 2.55 [1.00–6.57] 0.051 3.9% –
Multivariable analysis
 COMT Met158 1.73 [0.69–4.35] 0.243 32.8% 9.06 × 10−7
 PTSD 0.09 [0.03–0.26] 5.0 × 10−6 – –
 Age (y) 1.00 [0.98–1.03] 0.723
 No GCS deficit 1.86 [0.69–5.01] 0.218
OR >1 represents greater odds of higher six-month functional outcome score on GOSE. COMT = Catechol-O-Methyltransferase; CI = Confidence 
Interval; GOSE = Glasgow Outcome Scale Extended; OR = Odds Ratio; PTSD = post-traumatic stress disorder.
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